PRESS RELEASE 19th MARCH 2014

New Broad Street House
35 New Broad Street
London EC2M 1NH
Tel: +44 (0) 20 7194 8080
Fax: +44 (0) 1462 896781
Email: info@rosettacapital.com

www.rosettacapital.com

rosettacapitallimited

Unlocking value in the life science sector

ROSETTA CAPITAL LTD AND LEXINGTON PARTNERS ACQUIRES EQUITY INTERESTS IN TWENTY COMPANIES FROM CORPORATE VENTURE ARM OF MAJOR PHARMACEUTICAL COMPANY.

London, 19 March 2014. Rosetta Capital V L.P., an affiliate of Rosetta Capital Ltd ("Rosetta"), a leading international life sciences secondary direct investor, today announced that, with the backing of Lexington Partners, it has acquired the equity interests in twenty companies from the corporate venture group of a major pharmaceutical company.

"We are delighted to have completed this transaction with one of the world's leading pharmaceutical venture groups, and backed by the world's largest independent manager of secondary private equity and co-investment funds. It has been a collaborative process in which we have worked closely with the corporate venture team and Lexington Partners. This deal highlights Rosetta's ability to offer liquidity solutions to investors in the life science sector." said Dr Jonathan Hepple, a Partner in Rosetta.

This transaction is Rosetta's fifth since its first secondary direct in 2006. Rosetta invests in portfolios of shareholdings to provide liquidity to other investors or corporations that, for strategic reasons, wish to divest some or all of their assets or to access additional capital and resource to optimise investment outcomes. Rosetta offers flexibility in transaction and management structures to achieve such liquidity solutions.

Rosetta was advised by Kirkland & Ellis and Bluetower Associates, and Lexington by Macfarlanes.

About Lexington Partners

Lexington Partners is a leading global alternative investment manager primarily involved in providing liquidity to owners of private equity and other alternative investments and in making co-investments alongside leading private equity sponsors. Lexington Partners is the largest independent manager of secondary acquisition and co-investment funds with more than $25 billion in committed capital. Since 1990, Lexington has acquired over 2,200 secondary and co-investment interests through 475 transactions with a total value in excess of $30 billion, including $10 billion of syndications. Lexington also invests in private investment funds during their initial formation and has committed to more than 200 new funds in the U.S., Europe, and the Asia-Pacific region. Lexington currently employs more than 80 people and has offices strategically located in the major centers for private equity investing – New York, Boston, Menlo Park, London, and Hong Kong. Lexington also has senior advisors located in Asia, Australia, and Latin America.

Additional information may be found at www.lexingtonpartners.com.

About Rosetta Capital Ltd

Rosetta is a UK-based firm that invests in portfolios of direct venture capital investments in the life science sector. Rosetta's funds encompass life science companies across North America, Europe and Asia.

For more information, contact Jonathan Hepple: +44 7775 654140
jph@rosettacapital.com